BioMarin Pharmaceutical Inc.

NasdaqGS:BMRN Stock Report

Market Cap: US$10.6b

BioMarin Pharmaceutical Future Growth

Future criteria checks 3/6

BioMarin Pharmaceutical is forecast to grow earnings and revenue by 25.3% and 10.2% per annum respectively. EPS is expected to grow by 26.9% per annum. Return on equity is forecast to be 10.2% in 3 years.

Key information

25.3%

Earnings growth rate

26.86%

EPS growth rate

Biotechs earnings growth23.4%
Revenue growth rate10.2%
Future return on equity10.19%
Analyst coverage

Good

Last updated07 May 2026

Recent future growth updates

Recent updates

Seeking Alpha • May 06

BioMarin: 'Strong Buy' On VOXZOGO Expansion And Amicus Acquisition

Summary BioMarin Pharmaceutical remains a "Strong Buy," driven by pipeline progress, strategic acquisitions, and robust revenue guidance. BMRN's acquisition of Amicus Therapeutics adds GALAFOLD and POMBILITI + OPFOLDA, boosting 2026 revenue guidance to $3.825–$3.925 billion and targeting 20% YoY growth. VOXZOGO expansion into hypochondroplasia and ongoing clinical trials represent major catalysts, with topline Phase 3 data expected in Q2 2026. The BMN 401 and BMN 333 programs, alongside PALYNZIQ label expansion, further diversify BMRN's growth opportunities and de-risk the investment thesis. Read the full article on Seeking Alpha
Narrative Update • Apr 29

BMRN: Fair Value View Weighs Voxzogo Headwinds Against Amicus Acquisition Potential

Analysts have trimmed their average price target on BioMarin Pharmaceutical slightly, cutting fair value by about $0.30 to $55.36. They are factoring in a higher discount rate, modestly stronger long term growth and margins, and a slightly lower future P/E multiple following recent reassessments of the Voxzogo franchise and the planned Amicus acquisition.
Narrative Update • Apr 15

BMRN: Fair Value View Balances Voxzogo Risks And Amicus Opportunity

The analyst fair value estimate for BioMarin Pharmaceutical has been trimmed from about $60 to roughly $55.66 as analysts factor in a higher discount rate, a lower future P/E multiple, and mixed expectations around Voxzogo and the Amicus acquisition. Analyst Commentary Recent research on BioMarin reflects a mixed but generally constructive stance, with several firms revising price targets while keeping positive ratings.
Narrative Update • Apr 01

BMRN: Pending Amicus Deal Will Reshape Earnings Power Despite Treatment Franchise Risks

Analyst revisions point to a slightly lower blended fair value for BioMarin Pharmaceutical, trimming the price target by about $0.09 as analysts factor in mixed views on Voxzogo and the pending Amicus deal while keeping underlying growth, margin, and P/E assumptions broadly unchanged. Analyst Commentary Recent Street research reflects a split view on BioMarin, with most analysts still constructive on long term value creation while others focus on Voxzogo related risks and competitive pressures.
Narrative Update • Mar 18

BMRN: Amicus Acquisition Is Expected To Reshape Future Earnings Power

Analysts have nudged their fair value estimate for BioMarin to $88.96 from $88.65, citing updates to revenue growth, profit margin and future P/E assumptions as they reassess Voxzogo risks, competitive pressure and the potential impact of the Amicus acquisition. Analyst Commentary Recent street research paints a mixed picture for BioMarin, with analysts recalibrating expectations around Voxzogo, the Amicus acquisition and the broader rare disease portfolio.
Narrative Update • Mar 03

BMRN: Rare Disease Portfolio Expansion And Amicus Acquisition Will Drive Repricing

Our BioMarin Pharmaceutical update trims the fair value estimate slightly to $120 from $122, as analysts weigh higher long term growth and margin assumptions against a higher discount rate and a lower future P/E multiple. Recent Street price target moves now cluster in the mid to high $90s, with outliers as low as $55 and as high as $105.
Narrative Update • Feb 17

BMRN: Recent Coverage Shifts Will Support Higher Future Earnings Multiple

Analysts have trimmed their fair value estimate for BioMarin Pharmaceutical by roughly $2 to about $88.65. This reflects updated views on discount rates, revenue growth, profit margins, and future P/E assumptions drawn from recent Street research.
Narrative Update • Feb 03

BMRN: Shares Should Recover As Fresh Coverage Supports Higher Future Earnings Multiple

Analysts have lifted their price target for BioMarin Pharmaceutical by about US$1 to roughly US$91, citing updated assumptions around revenue growth, margins and a higher future P/E multiple, supported by recent positive Street research coverage. Analyst Commentary Bullish Takeaways Bullish analysts point to the recent Street coverage as support for using a higher future P/E multiple, which feeds directly into a slightly higher fair value range around US$91.
Narrative Update • Jan 20

BMRN: Reset Long Term Outlook Will Shape Risk Balance Going Forward

Analysts have reduced their price target on BioMarin Pharmaceutical to US$60 from US$67.39 as they factor in updated long term revenue scenarios, a higher discount rate, and slightly stronger margin assumptions following recent quarterly results and guidance changes. Analyst Commentary Recent Street research shows a cluster of price target cuts on BioMarin, generally following an "okay" Q3 print, a Q3 revenue miss in some areas, and updated long term guidance that now reflects a wider range of possible competitive and intellectual property outcomes.
Narrative Update • Jan 06

BMRN: Shares Should Recover As 2027 Revenue Reset Clarifies Competition Risk

Analysts now see fair value for BioMarin Pharmaceutical at $89.74 per share, a small move up that reflects lower long term revenue growth assumptions, a slightly higher profit margin outlook, and modestly higher future P/E expectations following recent price target cuts tied to Voxzogo trends, revised 2027 revenue guidance, and potential competition. Analyst Commentary Recent Street research shows a wide range of views on BioMarin, with a clear focus on Voxzogo trends, updated 2027 revenue scenarios, and the impact of potential competition on execution and valuation.
Narrative Update • Dec 16

BMRN: Shares Will Strengthen As 2025 Guidance Reset Supports Future Upside

Analysts have trimmed their average price target on BioMarin Pharmaceutical by roughly $1 to reflect a modest reset in long term revenue and margin expectations after Q3’s revenue miss, Voxzogo softness and greater acknowledgment of emerging competitive risks, even though they continue to view the shares as undervalued. Analyst Commentary Analyst reactions to BioMarin’s Q3 update reflect a more nuanced view of the company’s medium term growth profile, with reduced price targets but largely constructive ratings as investors recalibrate for competitive dynamics and updated long range guidance.
Narrative Update • Dec 02

BMRN: Shares Will Strengthen As 2025 Guidance and Pipeline Progress Drive Upside

BioMarin Pharmaceutical's analyst price target has been reduced from $90.50 to $89.36. Analysts cite slightly lower growth and profit margin expectations, new competitive pressures, and revised long-term guidance as key drivers for the change.
Narrative Update • Nov 18

BMRN: Shares Will Recover As Revenue Guidance Aligns With Market Expectations

Analysts have modestly reduced their price target for BioMarin Pharmaceutical, trimming it by $0.10 to $90.50. Recent updates reflect a more cautious outlook on revenue growth and profit margins in light of evolving competitive and regulatory expectations.
Narrative Update • Nov 03

BMRN: Revenue Guidance Revision Will Reveal New Competitive Dynamics Ahead

Analysts have lowered their average price target for BioMarin Pharmaceutical from about $94.80 to $90.60. This reflects a cautious view following revenue misses, reduced long-term guidance due to anticipated competition, and updated profit margin forecasts.
Analysis Article • Oct 30

Earnings Miss: BioMarin Pharmaceutical Inc. Missed EPS And Analysts Are Revising Their Forecasts

Last week, you might have seen that BioMarin Pharmaceutical Inc. ( NASDAQ:BMRN ) released its quarterly result to the...
Narrative Update • Oct 20

Pipeline Progress And Regulatory Support Will Unlock Rare Disease Opportunities

BioMarin Pharmaceutical's analyst price target was revised slightly lower, decreasing from $95.16 to $94.80 per share as analysts weighed ongoing competitive risks to Voxzogo and modest changes to key financial assumptions. Analyst Commentary Recent analyst coverage of BioMarin Pharmaceutical reflects a mix of optimism and caution surrounding the company's future prospects, especially regarding its growth story, competitive landscape, and valuation relative to peers.
Narrative Update • Oct 05

Pipeline Progress And Regulatory Support Will Unlock Rare Disease Opportunities

Analysts have slightly lowered their price target for BioMarin Pharmaceutical to $95.16. This adjustment reflects carefully balanced views on future revenue growth, competitive risks affecting key drugs, and the company's ongoing potential for pipeline advancement.
Analysis Article • Aug 06

Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

NasdaqGS:BMRN 1 Year Share Price vs Fair Value Explore BioMarin Pharmaceutical's Fair Values from the Community and...
Analysis Article • Jul 22

Investors Still Waiting For A Pull Back In BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

BioMarin Pharmaceutical Inc.'s ( NASDAQ:BMRN ) price-to-earnings (or "P/E") ratio of 20.7x might make it look like a...
Seeking Alpha • Jan 23

BioMarin Pharmaceuticals: Share Downdraft Combined With VOXZOGO Potential Makes A Buy

Summary BioMarin's stock has dropped over 26% since July 2024, raising questions about whether it's a bargain or a falling knife. Key issues include valuation, stock volatility, an underwhelming investor's day, and competition with their drug VOXZOGO. The sharp decline in share price invites a reassessment of BioMarin's current investment prospects. Investors need to weigh the potential for recovery against the risks of further declines. Read the full article on Seeking Alpha
Seeking Alpha • Nov 21

Biomarin: Challanges Mount, But Sale Rumours Make For A Risky "Buy" Call

Summary Biomarin has a near $3bn per annum rare disease drug franchise, and is profitable. Arguably the business is undervalued by the market. The company faces threats to key drugs in the indications of acondrophasia, hemophilia and patent expiry issues, making the medium term outlook tricky. Long term, a new management is promising $4bn of revenues by 2027, and long term mid-teen revenue growth. Elliott Investment Management is invested in the company and may be attempting to position the business for a sale. Management's forecasts may be over-ambitious, and Wall Street's current valuation of the business too low. The prospect of a sale tips the balance in favour of a "Buy" recommendation. Read the full article on Seeking Alpha
Seeking Alpha • Aug 21

BioMarin: Voxzogo Sales Surge Isn't Only Driving Force In 2024

Summary BioMarin Pharmaceutical Inc. sales of Voxzogo had increased by 62% to $184 million in Q2 of 2024, compared to the same period in 2023. Potential to eventually expand the use of Voxzogo towards other indications like hypochondroplasia and idiopathic short stature. Data from the phase 1/2 study, using BMN351 for the treatment of patients with DMD amenable to exon 51 skipping, expected by the end of 2024. The global Duchenne Muscular Dystrophy Treatment market size is expected to reach $8.19 billion by 2029; It is said that about 13% of DMD patients are amenable to exon 51 skipping. Read the full article on Seeking Alpha
Seeking Alpha • Jul 24

BioMarin Pharmaceutical: Steady Performer Scheduling Its Big Reveal In 09/2024

Summary BioMarin's shares have enjoyed three strong, albeit brief, updrafts in recent years. It plans to reveal its latest strategies for developing its rich portfolio of approved drugs at its 09/2024 investor's day. With ample liquidity and positive earnings BioMarin's financial profile is steady. Read the full article on Seeking Alpha
Seeking Alpha • May 15

BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain

Summary BioMarin's 1Q24 revenue was $649 million, with a 9% YoY increase, but uncertainty around the commercial prospects of Roctavian has dampened optimism. The company's core drug portfolio performed as expected, with some drugs exceeding consensus expectations and others falling short. Voxzogo remains a strong revenue driver, with sales of $153 million in 1Q24, and plans to expand into new indications, potentially significantly expanding the addressable market. I maintain my bullish view on BMRN stock, but it has become less bullish. My new fair price for BMRN is $112. Read the full article on Seeking Alpha

Earnings and Revenue Growth Forecasts

NasdaqGS:BMRN - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20284,8161,2551,36898714
12/31/20274,4181,0301,0871,15320
12/31/20263,87169397231920
3/31/20263,242269759874N/A
12/31/20253,221349717828N/A
9/30/20253,094520826914N/A
6/30/20253,064657691767N/A
3/31/20252,950524620700N/A
12/31/20242,854427485573N/A
9/30/20242,753322311415N/A
6/30/20242,588257223329N/A
3/31/20242,472205173280N/A
12/31/20232,41916852159N/A
9/30/20232,31114725139N/A
6/30/20232,23510034161N/A
3/31/20232,1737215147N/A
12/31/20222,096142148176N/A
9/30/20222,00884151180N/A
6/30/20221,91254106119N/A
3/31/20221,88039134146N/A
12/31/20211,846-64185305N/A
9/30/20211,84916165280N/A
6/30/20211,917837155269N/A
3/31/20211,84479592214N/A
12/31/20201,8608541585N/A
9/30/20201,86385275156N/A
6/30/20201,84712258140N/A
3/31/20201,805114388N/A
12/31/20191,704-24N/A48N/A
9/30/20191,603-43N/A40N/A
6/30/20191,533-110N/A17N/A
3/31/20191,519-90N/A8N/A
12/31/20181,491-77N/A20N/A
9/30/20181,496-125N/A-15N/A
6/30/20181,439-125N/A-23N/A
3/31/20181,383-145N/A29N/A
12/31/20171,314-117N/A-9N/A
9/30/20171,255-156N/A-24N/A
6/30/20171,201-181N/A-72N/A
3/31/20171,184-563N/A-137N/A
12/31/20161,117-630N/A-228N/A
9/30/20161,045-471N/A-293N/A
6/30/2016974-524N/A-286N/A
3/31/2016924-187N/A-253N/A
12/31/2015890-172N/A-219N/A
9/30/2015892-310N/A-179N/A
6/30/2015859-212N/A-185N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BMRN's forecast earnings growth (25.3% per year) is above the savings rate (3.5%).

Earnings vs Market: BMRN's earnings (25.3% per year) are forecast to grow faster than the US market (16.4% per year).

High Growth Earnings: BMRN's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: BMRN's revenue (10.2% per year) is forecast to grow slower than the US market (11.4% per year).

High Growth Revenue: BMRN's revenue (10.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: BMRN's Return on Equity is forecast to be low in 3 years time (10.2%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/07 19:54
End of Day Share Price 2026/05/07 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BioMarin Pharmaceutical Inc. is covered by 48 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Ying HuangBarclays
Eliana MerleBarclays